spacer
home > epc > autumn 2003 > new approaches to developing cancer drugs
PUBLICATIONS
European Pharmaceutical Contractor

New Approaches to Developing Cancer Drugs

The latest statistics make alarming reading: in the developed world one in three people will suffer from cancer and one in four will die from the disease. Due to an ageing population the worldwide incidence of cancer is predicted to double from 10 to 20 million by 2020 (WHO). Traditional approaches to cancer treatment rely on a combination of surgery, radiotherapy and chemotherapy. Current cancer drugs, which are mostly lethal for cells (cytotoxic), either affect DNA synthesis and the process of cell division or they react chemically with DNA to cause chromosomal damage.

These drugs have major limitations as they damage all proliferating cells and therefore produce considerable side effects. Drug resistance is another serious problem. Hence there is a major unmet need for more systematic but innovative and effective therapies for cancer treatment, especially for targeting early stages of the disease or later stage metastatic disease.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Gijsbertus J Pronk PhD, Senior Director, US Business Development at atugen AG

Gijsbertus J Pronk, PhD, is Senior Director in charge of US business development for atugen AG, Germany. Bert joined atugen, USA Inc in 2000 as Director of Research having formerly been Senior Scientist for Target Development with Chiron Corporation. Previously he held various research posts including a post-doctoral assignment in the laboratory of Dr Lewis T Williams at the Cardio-Vascular Research Institute (CVRI) at UC-San Francisco, where he studied programmed cell death (apoptosis).

spacer
Gijsbertus J Pronk
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Entry now open for the PPMA Group Industry Awards 2019

The 2019 PPMA Group Industry Awards will be held at the National Conference Centre (NEC), Birmingham, on the evening of the first day of the PPMA Total Show 2019 – Tuesday, 1 October 2019. 
More info >>

White Papers

How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction

Temptime Corporation

The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement